Cargando…

PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent

OBJECTIVE—: Macrophages are versatile immune cells capable of polarizing into functional subsets depending on environmental stimulation. In atherosclerotic lesions, proinflammatory polarized macrophages are associated with symptomatic plaques, whereas Th2 (T-helper cell type 2) cytokine–polarized ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hohensinner, Philipp J., Baumgartner, Johanna, Kral-Pointner, Julia B., Uhrin, Pavel, Ebenbauer, Benjamin, Thaler, Barbara, Doberer, Konstantin, Stojkovic, Stefan, Demyanets, Svitlana, Fischer, Michael B., Huber, Kurt, Schabbauer, Gernot, Speidl, Walter S., Wojta, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Translational Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627534/ https://www.ncbi.nlm.nih.gov/pubmed/28818858 http://dx.doi.org/10.1161/ATVBAHA.117.309383

Ejemplares similares

Changes of Circulating Extracellular Vesicles from the Liver after Roux-en-Y Bariatric Surgery
por: Rega-Kaun, Gersina, et al.
Publicado: (2019)

Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles
por: Hohensinner, Philipp J., et al.
Publicado: (2020)

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Cardioprotective cytokine interleukin‐33 is up‐regulated by statins in human cardiac tissue
por: Pentz, Richard, et al.
Publicado: (2018)

The Paradigm Change of IL-33 in Vascular Biology
por: Demyanets, Svitlana, et al.
Publicado: (2021)

Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients
por: Hohensinner, P. J., et al.
Publicado: (2018)

Surrogate Markers of Neutrophil Extracellular Trap Formation are Associated with Ischemic Outcomes and Platelet Activation after Peripheral Angioplasty and Stenting
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Neutrophil Extracellular Trap Degradation by Differently Polarized Macrophage Subsets
por: Haider, Patrick, et al.
Publicado: (2020)

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2
por: Stojkovic, Stefan, et al.
Publicado: (2018)

Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease—A 10-Year Cohort Study
por: Urban, Matthias H., et al.
Publicado: (2021)

Soluble ST2 as a Potential Biomarker for Abdominal Aortic Aneurysms—A Single-Center Retrospective Cohort Study
por: Klopf, Johannes, et al.
Publicado: (2022)

Bariatric surgery in morbidly obese individuals affects plasma levels of protein C and thrombomodulin
por: Rega-Kaun, Gersina, et al.
Publicado: (2018)

Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction
por: Hohensinner, Philipp J., et al.
Publicado: (2017)

Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting
por: Stojkovic, Stefan, et al.
Publicado: (2020)

An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis
por: Demyanets, Svitlana, et al.
Publicado: (2014)

PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Soluble ST2 in Patients with Carotid Artery Stenosis—Association with Plaque Morphology and Long-Term Outcome
por: Stojkovic, Stefan, et al.
Publicado: (2023)

Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome
por: Demyanets, Svitlana, et al.
Publicado: (2014)

Quantitative and Functional Assessment of the Influence of Routinely Used Cryopreservation Media on Mononuclear Leukocytes for Medical Research
por: Haider, Patrick, et al.
Publicado: (2022)

Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans
por: Thaler, B., et al.
Publicado: (2016)

Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)

G-CSF Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease
por: Katsaros, Katharina M., et al.
Publicado: (2015)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth.
por: Whur, P., et al.
Publicado: (1979)

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015)

Interleukin‐4 receptor alpha signaling regulates monocyte homeostasis
por: Haider, Patrick, et al.
Publicado: (2022)

ISG12 is a critical modulator of innate immune responses in murine models of sepsis()
por: Uhrin, P., et al.
Publicado: (2013)

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice
por: Kenny, Susan, et al.
Publicado: (2013)

Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
por: Party, Hélène, et al.
Publicado: (2019)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

Changes in plasminogen activator inhibitor-1 (PAI-1) in patients with severe sepsis or septic shock
por: Ikeda, T, et al.
Publicado: (2002)

Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in mice()
por: Gamble, Joanne, et al.
Publicado: (2013)

Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma
por: Kluft, C.
Publicado: (2000)

Monocyte subsets predict mortality after cardiac arrest
por: Krychtiuk, Konstantin A., et al.
Publicado: (2020)

Commentary on “Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism”: A new role for plasminogen activator inhibitor‐1—An inhibitor of fibrinolysis predicts future venous thromboembolic events and links them to obesity
por: Wojta, Johann
Publicado: (2022)

Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
Publicado: (1991)

Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells
Publicado: (1987)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_bsesd46dn5cpi6e2cajvv4ug1f